In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Leadership

What Does AI Excellence Look Like In Big Pharma?

Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.

C-Suite Speaks Digital Health Artificial Intelligence

Latest From Leadership

Digital Acceleration: Low-Hanging Fruit And Stretch Goals

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Coronavirus COVID-19 Digital Health

Using ‘Big’ For Good In The COVID-19 Challenge

Johnson & Johnson, among world’s largest health care groups, explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

Business Strategies Coronavirus COVID-19

Pharma Inc And Climate Change – Are China And India The Missing Link?

As of October 2020, nearly a thousand companies from all industries have committed to climate change-related “Science Based Targets.” However, only 17 signatories are from the pharmaceutical industry, and they are the usual suspects from big pharma. There are none from India and China.

Sustainability Business Strategies

Finding The Exit: Forbion On Roche’s Acquisition Of Inflazome

Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.

Europe Deals

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Commercial

Executive Recruiting: Culture, Convergence And COVID-19

COVID-19 has created an “always accessible” online work environment conducive to executive recruiting, although some candidates are hesitant to change jobs during pandemic-related uncertainty. Corporate culture and an accelerating digital convergence continue to drive hiring decisions, in addition to US immigration policy and a renewed emphasis on diversity, equity and inclusion.

Coronavirus COVID-19 Leadership
See All